Research Article
Pulmonary Complications Secondary to Immune Checkpoint Inhibitors
Table 2
Baseline characteristics of the 10 patients with pneumonitis secondary to ICI use.
| Baseline characteristics | Patients, no. (%) |
| Age (y) | | ≥65 | 4 (40) | <65 | 6 (60) | Male sex | 7 (70) | Body mass index >30 | 6 (60) | Positive smoking history (current and prior use) | 7 (70) | Cancer stage IV at time of pulmonary complications | 10 (100) | Site of metastasis | | Liver | 4 (40) | Bone | 6 (60) | Charlson comorbidity index | | 0-8 | 4 (40) | 9-17 | 6 (60) | Previous radiation history | 8 (80) | Chemotherapy before initiation of ICI use | | Yes | 7 (70) | No | 3 (30) | Medical history of COPD or emphysema | | Yes | 2 (20) | No | 8 (80) | Use of corticosteroid inhaler at time of pneumonitis | | Yes | 1 (0) | No | 9 (90) |
|
|
Abbreviations: COPD: chronic obstructive pulmonary disease; ICI: immune checkpoint inhibitor.
|